Background: Although numerous articles have addressed the risk of pulmonary embolism following total knee and total hip arthroplasty, we were unable to find comparable information for the risk following elbow arthroplasty. We therefore sought to determine the prevalence of pulmonary embolism after total elbow arthroplasty.
Methods: We conducted a retrospective review of the medical records of consecutive patients who had undergone primary elbow arthroplasty (816 procedures) or revision total elbow arthroplasty (260 procedures) at our tertiary-care academic medical institution between June 1981 and June 2001. Our purpose was to identify all patients in whom a pulmonary embolism developed after the surgery.
Results: Three patients had a pulmonary embolism and one died as a result of the complication during the twenty-year study period. Because of a low index of suspicion, the presenting symptoms of the pulmonary embolus were originally attributed to other causes of respiratory distress in two of the three patients.
Conclusions: These findings suggest that pulmonary embolism after total elbow arthroplasty is a rare but potentially fatal complication. Surgeons should consider this diagnosis when a patient exhibits respiratory distress after total elbow arthroplasty.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.2106/JBJS.F.01328 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
The adverse effects with ibuprofen after major orthopedic surgeries: A protocol for the PERISAFE randomized clinical trial.
Acta Anaesthesiol Scand
March 2025
Centre for Anaesthesiological Research, Department of Anesthesiology, Zealand University Hospital, Køge, Denmark.
Introduction: Non-steroidal anti-inflammatory drugs (NSAIDs) are recommended for pain treatment after elective hip and knee arthroplasties. However, evidence regarding the incidence of adverse effects with short-term NSAID treatment following surgery is limited. We, therefore, aim to assess the adverse effects with an eight-day postoperative treatment with ibuprofen after elective hip and knee arthroplasties.
View Article and Find Full Text PDFLow-dose Systemic Tissue-type-plasminogen-activator Compared to Conventional Anti-coagulation for the Treatment of Intermediate-high Risk Pulmonary Embolism.
Cardiovasc Hematol Disord Drug Targets
January 2025
Division of Pulmonary and Critical Care Medicine, Texas Tech University Health Sciences Center, El Paso, TX, USA.
Background: Pulmonary embolism (PE) is a frequent cause of death. Acute PE may be treated either with full anticoagulation (AC) alone or thrombolytic therapy with systemic tissue-- type-plasminogen-activator (tPA) based on risk assessment. Currently, AC is the standard of care for most patients with intermediate-high-risk PE, with low-dose tPA emerging as an effective alternative.
View Article and Find Full Text PDFPulmonary Embolism in a Palliative Aortopulmonary Shunt.
JACC Case Rep
January 2025
Department of Adult Congenital Heart Disease, University of Virginia, Charlottesville, Virginia, USA.
A 44-year-old man with a history of tricuspid atresia and discontinuous pulmonary arteries with palliative correction from a Waterston procedure and a modified central shunt presented with back pain, fevers, dyspnea, and cough. Treatment for pneumonia was unsuccessful. On computed tomography angiography he was found to have a subacute pulmonary embolism, potentially iatrogenic.
View Article and Find Full Text PDFThe routine use of Rivaroxaban as thromboprophylaxis following endovenous thermal ablation.
Vasa
January 2025
Department of Vascular Surgery, Aristotle University of Thessaloniki, AHEPA University General Hospital, Thessaloniki, Greece.
We investigated the safety and efficacy of rivaroxaban as routine thromboprophylaxis after endovenous thermal ablation (EVTA). Adhering to the PRISMA 2020 guidelines, we conducted a systematic review for studies published up to April 2024. Primary endpoints included endovenous heat-induced thrombosis (EHIT) class ≥ II, deep vein thrombosis (DVT), major and minor bleeding and the composite endpoint of major thromboembolic complications including any incidents of EHIT ≥ III, DVT or pulmonary embolism (PE).
View Article and Find Full Text PDFLeukoglycemic Index and Its Prognostic Implications in Diabetic and Nondiabetic Patients with Acute Pulmonary Embolism.
Med Sci Monit
January 2025
Department of Emergency Medicine, Sakarya University Faculty of Medicine, Adapazari, Turkey.
BACKGROUND The leuko-glycemic index (LGI) combines the white blood cell count and blood glucose levels and is calculated by multiplying the 2 values and dividing them by 1000. This study aimed to compare the prognostic value of the LGI in 199 patients with acute pulmonary embolism (APE) with and without diabetes mellitus. MATERIAL AND METHODS This study was conducted retrospectively on 199 patients who were admitted to the Emergency Department of Sakarya Training and Research Hospital between January 1, 2019, and December 31, 2022, and received a diagnosis of APE by pulmonary angiography.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!